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Non-tuberculous mycobacteria are increasingly being recognized as important human pathogens. We
present the case of a 44-year-old non-diabetic male who underwent left total knee arthroplasty for
degenerative arthritis after trauma. He developed left knee swelling and progressively worsening pain
over the next 4 weeks. He was referred for treatment using whirlpool baths and developed a blister at the
surgical incision site. Repeated aspirations of the left knee failed to show any growth of organism on
routine cultures. He ﬁnally underwent explantation of the left knee prosthesis with antimicrobial spacer
placement 4 months later. Cultures of three different intra-operative specimens turned positive for
Mycobacterium goodii. This infection was successfully treated with combination oral antimicrobials for 6
months. The patient underwent revision left knee arthroplasty subsequently and was symptom-free
until his last follow-up visit 1 year later. This patient highlights the importance of testing for
mycobacteria in prosthesis-related infections with previously negative routine bacterial cultures.
ß 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
Non-tuberculous mycobacteria, including Mycobacterium
goodii, are increasingly recognized as important human pathogens.
We report a patient with an M. goodii prosthesis-related knee
infection, the third reported case to our knowledge.
2. Case report
A 44-year-old non-diabetic male underwent left total knee
arthroplasty for degenerative arthritis following trauma secondary
to a motor vehicle accident. The accident, 19 years ago, had caused
a left femoral fracture, which at that time had required open
reduction/internal ﬁxation and nail placement. Post-knee surgery,
he developed left knee swelling and pain, which progressively
worsened over the next 4 weeks. Subsequently he underwent
osteopathic/chiropractic maneuvering, providing no relief of
symptoms. He was then referred for physical therapy, requiring
treatment in whirlpool baths. Soon after exposure to the whirlpool
bath (6–8 weeks after surgery), he developed a blister on the
anterior aspect of the left knee at the surgical incision site, for
which he used Epsom salts with no relief. Repeated aspirations of
the left knee failed to show any growth of organism on routine
cultures. He continued to have worsening pain and left knee
swelling and ﬁnally underwent explantation of the left knee
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prosthesis, with antimicrobial spacer placement 4 months later.
Prior to the procedure, the patient had been off antimicrobials for
almost 2 weeks.
The patient’s past medical history was signiﬁcant for nicotine
dependence, poor dental hygiene, and signiﬁcant ethanol use. On
examination he was a well appearing, afebrile male. The vital signs
were within normal limits. Musculoskeletal examination showed
left knee swelling with no erythema, drainage of ﬂuid, or
tenderness at the surgical incision site. The rest of the examination
was within normal limits.
The initial investigations showed an erythrocyte sedimentation
rate (ESR) of 88 mm/h and C-reactive protein (CRP) of 1.64 mg/dl.
An X-ray of the left knee showed surgical changes of the left knee
arthroplasty and patellar resurfacing, asymmetric narrowing of the
medial joint space, and left knee joint effusion. Histopathology of
the synovium demonstrated ﬁbrous connective tissue with patchy
chronic inﬂammation, but no granulomas.
The patient was empirically started on intravenous vancomycin
1250 mg every 12 h along with ceftriaxone 2 g every 24 h. Intraoperative tissue Gram stain and acid-fast stain were negative.
Cultures of three different intra-operative specimens turned
positive for acid-fast bacilli (AFB) within 3 days of surgery. DNA
sequence testing performed by a reference laboratory (Arup
Laboratories, Salt Lake City, Utah, USA) identiﬁed the organism as
M. goodii/smegmatis. Susceptibility testing using broth microdilution technique showed the organism to be susceptible to amikacin,
cefoxitin, ciproﬂoxacin, gatiﬂoxacin, linezolid, minocycline, trimethoprim/sulfamethoxazole (TMP/SMX), and tobramycin, and
resistant to clindamycin.
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Empiric antimicrobial treatment was then discontinued. The
patient was started on TMP/SMX 160/800 mg one tablet twice
daily, minocycline 100 mg one tablet twice daily, ciproﬂoxacin
500 mg one tablet twice daily. He stopped TMP/SMX 160/800 mg
one tablet twice daily on his own after 1 week. He continued with
minocycline and ciproﬂoxacin for 6 months. ESR and CRP
normalized with resolving left knee swelling and pain. He
underwent revision left total knee arthroplasty 6 months after
completing the antimicrobial course. The intra-operative AFB stain
and cultures were negative for mycobacteria. He was symptomfree at follow-up after 1 year.
3. Discussion
Mycobacterium smegmatis group was ﬁrst isolated by Lustgarten
in 1885. The ﬁrst well-described case of human disease caused by
the M. smegmatis group, involving the lungs and pleura of a patient
with underlying exogenous lipoid pneumonia, was reported in
1986. The ﬁrst series of patients with M. smegmatis infection was
reported by Wallace1 in 1988, who characterized 22 clinical
isolates that were heterogeneous and fell into three groups. In
1999, the three groups were studied in greater detail,2 including
DNA homologies, and were found to be three distinct species: M.
smegmatis sensu stricto, Mycobacterium wolinskyi, and M. goodii.
The most accurate differentiation of these species is accomplished
through molecular techniques.3
M. goodii has been implicated in localized post-traumatic
wound infections, surgical site infections, osteomyelitis following
open fractures, and pulmonary infections complicating lipoid
pneumonia or achalasia.1,4–6 Other reported cases include olecranon bursitis in a patient with diabetes and multiple myeloma7,
bacteremia and pacemaker lead infection,8 and post-cataract
endophthalmitis.9 The organism is found in the environment and is
able to survive inside free living fresh water amoeba.10 It is
relatively resistant to disinfectants.
Antimicrobial susceptibility data are sparse. The original study
by Brown et al.2 showed all isolates susceptible to amikacin,
doxycycline, ciproﬂoxacin, and sulfamethoxazole, and variably
susceptible to cefoxitin and clarithromycin. These organisms are
usually susceptible to ethambutol and exhibit good in vitro
susceptibility to gatiﬂoxacin and ciproﬂoxacin.11 Monotherapy
with TMP/SMX or doxycycline has been used, but often associated
with treatment failure, resulting in prolongation of course. Most
authors recommend 4 months of two-drug therapy for skin/soft
tissue infections and therapy of 6 months duration for underlying
bone disease, with removal of foreign body. Commonly used
antimicrobials include TMP/SMX, doxycycline, and ciproﬂoxacin.
Intravenous amikacin and imipenem have been used for severe
cases.12 The most recent case report of such an infection involving

a knee prosthesis was treated with moxiﬂoxacin and doxycycline
for 9 months, followed by monotherapy with doxycycline for life of
the retained prosthesis.13 In our patient, the prosthesis was
removed, which probably was the most important intervention
resulting in an eventually satisfactory outcome.
In conclusion, M. goodii is a rapidly growing mycobacterium
increasingly recognized as an important human pathogen. It is
most commonly implicated in post-trauma and surgical site
infections. It is also associated with respiratory infections in
patients with lipoid pneumonia. Identiﬁcation of the organism is
best accomplished by molecular techniques. Infection with this
organism may not produce granulomas. This patient highlights the
importance of testing for mycobacteria in prosthesis-related
infections with previously negative routine bacterial cultures.
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